image
OrganiGram Holdings Inc. OGI
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - CA
Watchlist
$ 1.44
-4 %
$ 156 M
Market Cap
-0.8
P/E
1. INTRINSIC VALUE

Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including cannabis flowers, cannabis oils, and vaporizers for civilian patients and veterans; adult use recreational cannabis under the Edison Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour brands; and cannabis edibles products and concentrates. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc.[ Read More ]

The intrinsic value of one OGI stock under the base case scenario is HIDDEN Compared to the current market price of 1.44 USD, OrganiGram Holdings Inc. is HIDDEN

OGI Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart OGI

image
FINANCIALS
149 M REVENUE
2.33%
Growth Rates
1Year 2.33%
3Years 19.79%
5Years 64.39%
7Years 57.79%
10Years 0.00%
-48.8 M OPERATING INCOME
-25.90%
Growth Rates
1Year -25.90%
3Years 30.53%
5Years -18.53%
7Years -69.48%
10Years -62.71%
-229 M NET INCOME
-1506.65%
Growth Rates
1Year -1506.65%
3Years -19.01%
5Years -62.62%
7Years -122.74%
10Years -89.95%
-35.8 M OPERATING CASH FLOW
1.15%
Growth Rates
1Year 1.15%
3Years 7.43%
5Years -23.02%
7Years -53.63%
10Years -70.45%
4.56 M INVESTING CASH FLOW
-89.64%
Growth Rates
1Year -89.64%
3Years 26.68%
5Years 15.40%
7Years 11.69%
10Years 85.24%
-754 K FINANCING CASH FLOW
-14.15%
Growth Rates
1Year -14.15%
3Years -0.16%
5Years -0.09%
7Years -0.29%
10Years -108.76%
41.1 M REVENUE
9.12%
Growth Rates
1Year 2.33%
3Years 19.79%
5Years 64.39%
7Years 57.79%
10Years 0.00%
-5.05 M OPERATING INCOME
79.29%
Growth Rates
1Year -25.90%
3Years 30.53%
5Years -18.53%
7Years -69.48%
10Years -62.71%
2.82 M NET INCOME
110.41%
Growth Rates
1Year -1506.65%
3Years -19.01%
5Years -62.62%
7Years -122.74%
10Years -89.95%
-2.51 M OPERATING CASH FLOW
69.62%
Growth Rates
1Year 1.15%
3Years 7.43%
5Years -23.02%
7Years -53.63%
10Years -70.45%
-16.1 M INVESTING CASH FLOW
-515.88%
Growth Rates
1Year -89.64%
3Years 26.68%
5Years 15.40%
7Years 11.69%
10Years 85.24%
26.1 M FINANCING CASH FLOW
-36.24%
Growth Rates
1Year -14.15%
3Years -0.16%
5Years -0.09%
7Years -0.29%
10Years -108.76%
Balance Sheet Decomposition OrganiGram Holdings Inc.
image
Current Assets 156 M
Cash & Short-Term Investments 33.9 M
Receivables 27.5 M
Other Current Assets 94.7 M
Non-Current Assets 142 M
Long-Term Investments 13.7 M
PP&E 99 M
Other Non-Current Assets 29.7 M
Current Liabilities 22.4 M
Accounts Payable 20 M
Short-Term Debt 76 K
Other Current Liabilities 2.35 M
Non-Current Liabilities 4.4 M
Long-Term Debt 3.63 M
Other Non-Current Liabilities 771 K
EFFICIENCY
Earnings Waterfall OrganiGram Holdings Inc.
image
Revenue 149 M
Cost Of Revenue 114 M
Gross Profit 35.1 M
Operating Expenses 271 M
Operating Income -48.8 M
Other Expenses 181 M
Net Income -229 M
RATIOS
23.51% GROSS MARGIN
23.51%
Averages
1Year 23.51%
3Years 3.09%
5Years 0.89%
7Years -37.95%
10Years -11.34%
-32.70% OPERATING MARGIN
-32.70%
Averages
1Year -32.70%
3Years -58.42%
5Years -67.22%
7Years -34.08%
10Years -33.57%
-153.80% NET MARGIN
-153.80%
Averages
1Year -153.80%
3Years -110.34%
5Years -99.94%
7Years -75.04%
10Years -64.09%
-84.48% ROE
-84.48%
Averages
1Year -84.48%
3Years -38.31%
5Years -32.66%
7Years -23.61%
10Years -115.66%
-76.89% ROA
-76.89%
Averages
1Year -76.89%
3Years -34.43%
5Years -27.62%
7Years -20.44%
10Years -32.15%
-17.99% ROIC
-17.99%
Averages
1Year -17.99%
3Years -14.99%
5Years -15.04%
7Years -11.03%
10Years -55.18%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis OrganiGram Holdings Inc.
image
Net Income -229 M
Depreciation & Amortization 24.1 M
Capital Expenditures -26.9 M
Stock-Based Compensation 5.29 M
Change in Working Capital 12.5 M
Others 152 M
Free Cash Flow -62.7 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets OrganiGram Holdings Inc.
image
OGI has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION

Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States.

image
5.64 USD
CRON
Undervalued 180.75%

Aurora Cannabis Inc. produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities.

image
3.81 USD
ACB
Overvalued 9.24%

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Cannabis Operations and Retail Operations segments.

image
0 USD
SNDL
Overvalued 100.00%

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany.

image
5.61 USD
CGC
Undervalued 50.48%

Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally.

image
4.83 USD
TLRY
Undervalued 258.08%
6. Ownership
Insider Ownership OrganiGram Holdings Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
Organigram: Why I Still Like It Organigram's stock has surged 22% since my last analysis, outperforming the cannabis market, yet it remains a buy due to its promising chart and valuation. The fiscal Q3 report exceeded expectations with revenue up 25% and adjusted EBITDA turning positive, highlighting significant financial improvement and strong cash reserves. Analysts have raised their projections for FY25 and FY26, expecting higher revenue and adjusted EBITDA, reinforcing the stock's attractive valuation and growth potential. seekingalpha.com - 2 months ago
3 Marijuana Stocks To Watch In The Stock Market Today Many legal cannabis operators are working to keep pushing the boundaries of the industry. Innovation is key for any growing sector and cannabis is no different. Right now is a pivotal time for the cannabis industry as things are continuously changing. The climate of the sector and the success of companies can have a direct connection to how most marijuana stocks perform, especially during an election year where promises may come along from presidential candidates to better the industry. marijuanastocks.com - 2 months ago
CPS HR Consulting Partners with GovInvest to Revolutionize Compensation Consulting with Advanced Technology SACRAMENTO, Calif.--(BUSINESS WIRE)--CPS HR Consulting, a leader in public sector HR consulting, is thrilled to announce a strategic partnership with GovInvest, the pioneer of compensation analytics technology for government agencies. This collaboration aims to combine CPS HR's renowned compensation consulting expertise with GovInvest's innovative software platform, offering unparalleled data confidence and decision-making capabilities. Highlights of the Partnership Best-in-Class Consulting + T. businesswire.com - 2 months ago
Organigram Closes Second Tranche of Previously Announced BAT Private Placement Investment TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today that on August 30, 2024, the Company closed the second of three tranches (the “Second Tranche”) of the previously announced C$124,559,674 follow-on strategic equity investment (the “Investment”) by BT DE Investments Inc. (the “Investor”), a wholly owned subsidiary of British American Tobacco plc (“BAT”). Pursuant to the Second Tra. businesswire.com - 2 months ago
Top Canadian Marijuana Stocks To Watch In 2024 When it comes to finding top marijuana stocks to buy which companies would you choose? Now when going through this process there are some things to consider. For the most part, investing in all things is based on the same basic outline which is buy low sell high do your research create a game plan be patient, and try to take profits when you can. marijuanastocks.com - 2 months ago
Next Week's Top Marijuana Stocks: Recent Big Gainers to Watch The cannabis industry is buzzing with recent developments that could significantly impact its future. In July 2024, the U.S. Senate reintroduced the SAFE Banking Act to provide cannabis businesses with greater access to banking services. This move has reignited optimism in the sector, as it could alleviate some of the financial constraints faced by cannabis companies. Additionally, several states, including Florida and Ohio, are pushing forward with ballot initiatives that could legalize recreational marijuana by the end of the year. These legislative efforts, combined with the growing momentum for federal legalization, are fueling investor interest in marijuana penny stocks. marijuanastocks.com - 2 months ago
Organigram: Q3 2024 Earnings Show Improvement In Revenues And Net Income (Hold) Organigram reported improved 3Q 2024 results. The company holds lead position in the Canadian cannabis market and is increasing its international cannabis exports. OGI stock price trades below its NAV per share and is undervalued. seekingalpha.com - 3 months ago
Why Is Organigram (OGI) Stock Up 25% Today? Organigram (NASDAQ: OGI ) stock is rising higher on Tuesday after the Canadian cannabis company released its most recent earnings report. The big news here is the company reporting C$41.06 million in revenue for its fiscal third quarter of the year. investorplace.com - 3 months ago
Organigram Holdings Inc. (OGI) Q3 2024 Earnings Call Transcript Organigram Holdings Inc. (NASDAQ:OGI ) Q3 2024 Earnings Conference Call August 13, 2024 8:00 AM ET Company Participants Max Schwartz - Director of Investor Relations Beena Goldenberg - Chief Executive Officer Greg Guyatt - Chief Financial Officer Conference Call Participants Aaron Grey - AGP Pablo Zuanic - Zuanic & Associates Frederico Gomes - ATB Capital Markets Yewon Kang - Canaccord Genuity Operator Good morning. My name is Keyla, and I'll be your conference operator today. seekingalpha.com - 3 months ago
Organigram's stock rises as Canadian pot company's revenue tops analyst estimate OrganiGram Holdings Inc.'s stock OGI, -2.04% was up 4% in premarket trading Wednesday after the Canadian cannabis producer reported beter-than-expected revenue. OrganiGram swung to third-quarter net income of C$2.82 million ($2.05 million), from a loss of C$213.45 million in the year-ago quarter. marketwatch.com - 3 months ago
Organigram Reports Third Quarter Fiscal 2024 Results TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the third quarter ended June 30, 2024 (“Q3 Fiscal 2024”). THIRD QUARTER HIGHLIGHTS Third quarter net revenue increased 25% to $41.1 million compared to $32.8 million in the same prior-year period Adjusted gross margin1 of $14.6 million or 36%, compared to $6.1 or 19% in the same prior- year period Net income of $2.8 mill. businesswire.com - 3 months ago
Organigram to Report Third Quarter Fiscal 2024 Results on August 13, 2024 TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its third quarter fiscal 2024 ended June 30, 2024, on Tuesday, August 13, 2024, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, August 13, 2024 Time: 8:00 am Eastern Time. businesswire.com - 3 months ago
8. Profile Summary

OrganiGram Holdings Inc. OGI

image
COUNTRY CA
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 156 M
Dividend Yield 0.00%
Description Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including cannabis flowers, cannabis oils, and vaporizers for civilian patients and veterans; adult use recreational cannabis under the Edison Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour brands; and cannabis edibles products and concentrates. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.
Contact 35 English Drive, Moncton, NB, E1E 3X3 https://www.organigram.ca
IPO Date May 21, 2019
Employees 914
Officers Mr. Timothy Emberg Chief Commercial Officer Mr. Greg Guyatt C.A., CPA Chief Financial Officer Mr. Paolo De Luca C.A., C.F.A Chief Strategy Officer Ms. Megan Amber McCrae Senior Vice President of Marketing & Communications Ms. Beena G. Goldenberg Chief Executive Officer & Director Ms. Nathalie Batten Senior Vice President of Operations Ms. Katrina May McFadden Chief People Officer Ms. Helen Martin Chief Legal Officer & Corporate Secretary Mr. Geoff Riggs Chief Information Officer Max Schwartz Director of Investor Relations